Search

Your search keyword '"Di Mola, Antonia"' showing total 233 results
Start Over Author "Di Mola, Antonia"
233 results on '"Di Mola, Antonia"'

4. An Effective Method for the Evaluation of the Enantiomeric Purity of 1,2-Diacyl- sn -glycero-3-phosphocholine-Based Lipids by NMR Analysis.

Author

Di Mola, Antonia, de Ferra, Lorenzo, Anibaldi, Mauro, Monaco, Guglielmo, and Massa, Antonio

Subjects
*LIPID analysis, *ACYL group, *EVALUATION methodology, *BORONIC acids, *GLYCOLS, *METHANOLYSIS, *FATTY acids, *ENANTIOMERIC purity
Abstract

In this article, we report a very efficient method for the determination of the enantiopurity of 1,2-diacyl-sn-glycero-3-phosphocholine by 1H NMR analysis using a readily available chiral derivatizing boronic acid (CDA), (R)-(2-(((1-phenylethyl)amino)methyl)phenyl)boronic acid. After the removal of the acyl groups of 1,2-diacyl-sn-glycero-3-phosphocholine via methanolysis and washing fatty acid byproducts with CHCl3, the obtained sn-glycero-3-phosphocholine (GPC) with the free diol moiety is derivatized by the chiral boronic acid and analyzed by 1H NMR analysis. The choline methyl resonance of each diastereomer is observed at distinctive chemical shifts in the 1H NMR spectrum. Integration of the respective resonances allows direct determination of the enantiomeric purity. The procedure was tested successfully using 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) with different enantiomeric purities and with commercially available 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. BIOLOGICAL ASPECTS OF NEW MOLECULAR THERAPIES FOR NEUROPATHOLOGIES.

Author

PICCIALLI, ILARIA, GRECO, FRANCESCA, ROVIELLO, GIOVANNI N., SISALLI, MARIA JOSÈ, TEDESCHI, VALENTINA, DI MOLA, ANTONIA, BORBONE, NICOLA, DE FEO, VINCENZO, SECONDO, AGNESE, MASSA, ANTONIO, PANNACCIONE, ANNA, NOLLI, MARIA GRAZIA, and OLIVIERO, GIORGIA

Subjects
ALZHEIMER'S disease, BIOLOGICAL assay, NEUROLOGICAL disorders, THIOFLAVINS
Abstract

Introduction: Addressing the formidable therapeutic hurdles posed by Alzheimer's disease (AD), our study delves into the central role of amyloid β 1-42 (Aβ1-42) protein aggregation in its onset. Aim: Our investigation aims to assess the therapeutic potential of the isoindolinone derivative 3-(3-oxoisoindolin-1-yl)pentane-2,4-dione (ISOAC1) against the Aβ1-42-induced toxicity. Material and methods: Employing a combination of thioflavin T fluorescence assay and biological and cellular approaches, alongside other experimental methods, we explored ISOAC1's ability to mitigate Aβ1-42 aggregation and toxicity. Results and conclusions: Our study unveils ISOAC1's capacity to disrupt Aβ1-42 aggregation and impede its transition towards β-sheet structures. Furthermore, our findings shed light on ISOAC1's binding mechanisms with Aβ1-42, indicating its promise as a therapeutic agent. ISOAC1 emerges as a compelling neuroprotective compound, offering novel avenues for AD treatment. [ABSTRACT FROM AUTHOR]

Published
2024

38. EXPLORING THE NEUROPROTECTIVE EFFECTS OF SYNTHETIC COMPOUNDS FOR NEW NEURODRUG DEVELOPMENT.

Author

PICCIALLI, ILARIA, GRECO, FRANCESCA, VICIDOMINI, CATERINA, SISALLI, MARIA JOSÈ, TEDESCHI, VALENTINA, DI MOLA, ANTONIA, BORBONE, NICOLA, OLIVIERO, GIORGIA, DE FEO, VINCENZO, SECONDO, AGNESE, MASSA, ANTONIO, PANNACCIONE, ANNA, NOLLI, MARIA GRAZIA, EWERT, ERNEST, FIK-JASKÓLSKA, MARTA, and ROVIELLO, GIOVANNI N.

Subjects
ALZHEIMER'S disease, AMYLOID, NEUROPROTECTIVE agents, WESTERN immunoblotting, TREATMENT effectiveness, THIOFLAVINS
Abstract

Introduction: Alzheimer's disease (AD) presents significant therapeutic challenges, with amyloid β1-42 (Aβ1-42) protein aggregation playing a central role in its pathogenesis. Aim: Our study investigates the potential therapeutic efficacy of the isoindolinone derivative 3-(3-oxoisoindolin-1-yl)pentane-2,4-dione (ISOAC1) against Aβ1-42-induced toxicity. Material and methods: We employed spectroscopic and computational approaches to explore ISOAC1's ability to mitigate Aβ1-42 aggregation and its consequent toxicity. Other experimental analyses included Thioflavin T fluorescence assay, and Western blotting. Results: Our findings reveal ISOAC1's capacity to disrupt Aβ1-42 aggregation and hinder its transition towards β-sheet structures. Computational investigations elucidate ISOAC1's binding mechanisms with Aβ1-42, highlighting its potential as a therapeutic agent. Conclusions: ISOAC1 emerges as a promising neuroprotective compound, offering insights into novel therapeutic strategies for AD treatment. The combined spectroscopic and computational approach herein presented provides a comprehensive understanding of ISOAC1's mechanism of action against Aβ1-42-induced toxicity. [ABSTRACT FROM AUTHOR]

Published
2024

39. Correction: Monaco et al. Chiral  Phase Transfer Catalysis in the Asymmetric Synthesis of a 3,3-Disubstituted Isoindolinone and Determination of Its Absolute Configuration by VCD Spectroscopy. Molecules 2020, 25 , 2272.

Author

Monaco, Guglielmo, Tiffner, Maximilian, Di Mola, Antonia, Herrebout, Wouter, Waser, Mario, and Massa, Antonio

Subjects
PHASE-transfer catalysis, ASYMMETRIC synthesis, MOLECULES, SPECTROMETRY
Abstract

In the paper, the VCD analysis was performed on the sample (+) B 1 b to determine its absolute configuration and it was found that the AC is ( I R i ). In this note, we report a correction to the published article, I Molecules i B 2020 b , I 25 i , 2272; doi:10.3390/molecules25102272 [[1]], regarding the absolute configuration (AC) of the used catalyst B IV b in the preparation of the sample sent for a VCD analysis. Chiral Phase Transfer Catalysis in the Asymmetric Synthesis of a 3,3-Disubstituted Isoindolinone and Determination of Its Absolute Configuration by VCD Spectroscopy. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results